Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: An OMERACT cohort validation study

Annals of the Rheumatic Diseases

Volumn 72, Issue 11, 2013, Pages 1800-1805

  Van Der Maas, Aatke ^a   Lie, Elisabeth ^b   Christensen, Robin ^c   Choy, Ernest ^d   De Man, Yaël A ^e   Van Riel, Piet ^f   Woodworth, Thasia ^g   Den Broeder, Alfons A ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c Copenhagen University Hospital ^*  (Denmark)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONSTRUCT VALIDITY; CONTROLLED STUDY; CRITERION RELATED VALIDITY; DAS28; DATA BASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NORWAY; OBSERVATIONAL STUDY; PHYSICIAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGISTER; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; VALIDATION STUDY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84885176968     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202281     Document Type: Article

References (28)

1. Bingham CO III, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335-41.
2. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
3. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
4. van Gestel AM, Prevoo ML, Van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
5. van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999;26:705-11.
6. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
7. Alten R, Pohl C, Choy EH, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745-50.
8. Bingham CO III, Alten R, Bartlett SJ, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751-8.
9. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
10. den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford) 2010;49:1801-3.
11. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2): CD008794.
12. Berthelot JM, De BM, Morel J, et al. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The 'FLARE' instrument. Ann Rheum Dis 2012;71:1110-16.
13. den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) 2002;41:638-42.
14. van den Bemt BJ, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008;67:1697-701.
15. de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59:1241-8.
16. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
17. Van der Cruyssen B, Durez P, Westhovens R, et al. The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther 2010;12:R169.
18. Assous N, Gossec L, Dieude P, et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008;35:31-4.
19. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
20. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010;37: 917-27.
21. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71: 1849-54.
22. Lie E, van der Heijde D, Uhlig T, et al. Treatment strategies inpatients with rheumatoid arthritis for whom methotrexatemonotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 2011;70:2103-10.
23. van der Maas A, van den Bemt B, Wolbink GJ, et al. Prevalence and reliability of low infliximab serum trough levels and Human Anti-Chimeric Antibodies (HACA) in RA patients with low disease activity in daily clinical practice. Arthritis Rheum 2010;62(Suppl 10):1826.
24. Terwee CB, Bot SD, De Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
25. Prevoo ML, Van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
26. Ware JE Jr, Kosinski M, Gandek B. SF-36 health survey: manual & interpretation guide. Lincoln, RI: Quality Metric Incorporated, 2005.
27. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
28. Lie E, Woodworth TG, Christensen R, et al. Exploration of OMERACT preliminary Rheumatoid Arthritis (RA) flare domains in a longitudinal observational study. Ann Rheum Dis 2012;71(Suppl 3):140.